NCT07416409 2026-02-18
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Deraya University
Completed
Deraya University
Novartis
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline